Cell Signaling Technology

Product Pathways - Neuroscience

TrkA (14G6) Rabbit mAb #2508

Applications Reactivity Sensitivity MW (kDa) Isotype
W IHC-P H Endogenous 140 Rabbit IgG

Applications Key:  W=Western Blotting  IHC-P=Immunohistochemistry (Paraffin)
Reactivity Key:  H=Human
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

TrkA (14G6) Rabbit mAb detects endogenous levels of total TrkA protein. This antibody does not cross-react with TrkB.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide surrounding Arg220 of human TrkA.

Western Blotting

Western Blotting

Western blot analysis of extracts from NIH/3T3, NIH/3T3-TrkA, NIH/3T3-TrkB and NIH/3T3-TrkC and K562 cells using TrkA (14G6) Rabbit mAb (upper) TrkB (80G2) Rabbit mAb Antibody #4607 (middle) and PLCγ1 Antibody #2822 (lower).

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human breast using TrkA (14G6) Rabbit mAb.

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human breast carcinoma using Trk A (14G6) Rabbit mAb #2508 in the presence of control peptide (left) or Trk A Blocking Peptide #1435 (right).


Background

The family of Trk receptor tyrosine kinases consists of TrkA, TrkB and TrkC. While the sequence of these family members is highly conserved, they are activated by different neurotrophins: TrkA by NGF, TrkB by BDNF or NT4, and TrkC by NT3. TrkA regulates proliferation and is important for development and maturation of the nervous system (1). Phosphorylation at Tyr490 is required for Shc association and activation of the Ras-MAP kinase cascade. Residues Tyr674/675 lie within the catalytic domain, and phosphorylation at this site reflects TrkA kinase activity (2-6). Point mutations, deletions and chromosomal rearrangements (chimeras) cause ligand-independent receptor dimerization and activation of TrkA. Many malignancies including breast, colon, prostate and thyroid carcinomas and acute myeloid leukemia have activated TrkA. Expression of TrkA in neuroblastomas is a good prognostic marker because it signals growth arrest and differentiation of cells originating from the neural crest (1).

  1. Pierotti, M.A. and Greco, A. (2006) Cancer Lett 232, 90-8.
  2. Segal, R.A. and Greenberg, M.E. (1996) Annu Rev Neurosci 19, 463-89.
  3. Stephens, R.M. et al. (1994) Neuron 12, 691-705.
  4. Obermeier, A. et al. (1993) EMBO J 12, 933-41.
  5. Obermeier, A. et al. (1994) EMBO J 13, 1585-90.
  6. Yao, R. and Cooper, G.M. (1995) Science 267, 2003-6.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

Rabbit Monoclonals Produced Using Epitomics® Technology, U.S. Patent No. 5,675,063.

This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.

Products